Alcami Appoints New Chairman and CEO

March 18, 2021
BioPharm International Editors

Patrick D. Walsh will take over the role from Walter J. Kaczmarek III, who is stepping down as CEO.

Alcami announced on March 18, 2021 that its board of directors has named Patrick D. Walsh as its new chairman and CEO. Walsh will take over the role from Walter J. Kaczmarek III, who is stepping down as CEO.

Before joining Alcami, Walsh served as CEO of AAIPharma Services, a predecessor company to Alcami, from 2010 to 2014; CEO of Avista Pharma from 2015 to 2019; and most recently served as co-founder and CEO of TriPharm Services, a parenteral manufacturing business, according to an Alcami press release. Along with his duties at Alcami, Walsh currently serves as chairman of ANI Pharmaceuticals, a director at Landec Corporation, and a director at Industria Chemica Emiliano.

"Patrick's impressive track record of driving growth and achieving high client satisfaction at leading pharmaceutical businesses makes him the ideal executive to lead Alcami forward,” said Jason Shideler, a managing director on Madison Dearborn Partners’ Health Care team and lead director at Alcami, in the press release. “He brings a depth of industry knowledge and leadership experience that will support Alcami’s strategic efforts to continue to add scale in attractive growth markets and deliver high-quality services to the pharmaceutical industry.”

"I have long-admired Alcami for its excellent regulatory track record and ability to solve complex product development and manufacturing challenges,” Walsh added in the press release. “I look forward to working with the talented team at Alcami as we continue to expand its footprint and build upon its services offerings."

Source: Alcami